Literature DB >> 2776111

Benign metastasizing giant cell tumors of bone. A DNA flow cytometric study.

M Ladanyi1, F Traganos, A G Huvos.   

Abstract

Approximately 2% of histologically benign giant cell tumors (BGCT) of bone are complicated by lung metastases, which can progress despite their benign histologic appearance. Almost all BGCT studied by DNA flow cytometry (FCM) have been reported to be diploid. However, the very few cases with lung metastases previously analyzed were all aneuploid. To assess the usefulness of DNA FCM in predicting the metastatic potential of BGCT, seven metastasizing BGCT were studied by DNA FCM using paraffin-embedded tissue. Five were purely diploid, one was tetraploid, and one was aneuploid. The primary and the metastasis showed the same DNA distribution in all but the tetraploid case, in which the metastasis was purely diploid. A single patient, who was in the diploid group, had unresectable tumor in the lungs; she remains alive with stable disease at 30 months. The other six patients, who underwent complete resections of their lung metastases, are free of disease. These results suggest that DNA FCM is not a sensitive method for predicting the metastatic potential of BGCT since most metastasizing cases appear to be diploid.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776111     DOI: 10.1002/1097-0142(19891001)64:7<1521::aid-cncr2820640727>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Case report 757: Giant cell tumor of rib.

Authors:  R M Hanna; M Kyriakos; S F Quinn
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

2.  Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone.

Authors:  M Alberghini; K Kliskey; T Krenacs; P Picci; L Kindblom; R Forsyth; N A Athanasou
Journal:  Virchows Arch       Date:  2009-12-15       Impact factor: 4.064

3.  Proliferation of osteoclast-like giant cells in a metastatic bone tumor from stomach cancer: report of a case and analysis of the autopsy findings.

Authors:  T Saeki; K Mandai; S Moriwaki; K Yamagami; N Sakamoto; W Takiyama; S Takashima
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities?

Authors:  Seethalakshmi Viswanathan; N A Jambhekar
Journal:  Clin Orthop Relat Res       Date:  2009-07-14       Impact factor: 4.176

5.  Recurrent pulmonary metastases from benign giant cell tumors of the bone: report of two cases and analysis of nuclear DNA content by flow cytometry.

Authors:  I Takanami; T Imamura; N Morota; S Kodaira
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

6.  Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion.

Authors:  Y Ueda; K Imai; H Tsuchiya; N Fujimoto; I Nakanishi; S Katsuda; M Seiki; Y Okada
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

7.  Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.

Authors:  Y Ueda; B Dockhorn-Dworniczak; S Blasius; W Mellin; P Wuisman; W Böcker; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Case report 869. Benign metastasizing giant cell tumor of bone.

Authors:  T Nojima; N Takeda; T Matsuno; K Inoue; K Nagashima
Journal:  Skeletal Radiol       Date:  1994-10       Impact factor: 2.199

9.  Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.

Authors:  M H Zheng; Y Fan; A Panicker; A Smith; T Robertson; S Wysocki; P Robbins; J M Papadimitriou; D J Wood
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

10.  Outcome of lung metastases due to bone giant cell tumor initially managed with observation.

Authors:  Shinji Tsukamoto; Giovanni Ciani; Andreas F Mavrogenis; Cristina Ferrari; Manabu Akahane; Yasuhito Tanaka; Michele Rocca; Alessandra Longhi; Costantino Errani
Journal:  J Orthop Surg Res       Date:  2020-11-07       Impact factor: 2.359

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.